Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Colombo, G. Ferrari, A. Stoppacciaro, M. Parenza, M. Rodolfo, F. Mavilio, G. Parmiani (1991)Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo
The Journal of Experimental Medicine, 173
B. Gansbacher, K. Zier, Brian Daniels, K. Cronin, R. Bannerji, E. Gilboa (1990)Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity
The Journal of Experimental Medicine, 172
Paul Golumbek, Rosa Azhari, Elizabeth Jaffee, Hyam Levitsky, Audrey Lazenby, Kam Leong, Drew Pardoll (1993)Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design.
Cancer research, 53 24
A. Huang, P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, H. Levitsky (1994)Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens.
Science, 264 5161
R. Schleimer, S. Sterbinsky, James Kaiser, C. Bickel, D. Klunk, K. Tomioka, W. Newman, F. Luscinskas, M. Gimbrone, B. McIntyre (1992)IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium. Association with expression of VCAM-1.
Journal of immunology, 148 4
A. Porgador, E. Tzehoval, A. Katz, E. Vadai, M. Revel, M. Feldman, L. Eisenbach (1992)Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells.
Cancer research, 52 13
R. Mulligan (1993)The basic science of gene therapy.
Science, 260 5110
Yoshihiko Watanabe, K. Kuribayashi, S. Miyatake, K. Nishihara, E. Nakayama, T. Taniyama, T. Sakata (1989)Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity.
Proceedings of the National Academy of Sciences of the United States of America, 86 23
J. Lindenmann, P. Klein (1967)VIRAL ONCOLYSIS: INCREASED IMMUNOGENICITY OF HOST CELL ANTIGEN ASSOCIATED WITH INFLUENZA VIRUS
The Journal of Experimental Medicine, 126
H. Hock, M. Dorsch, T. Diamantstein, T. Blankenstein (1991)Interleukin 7 induces CD4+ T cell-dependent tumor rejection
The Journal of Experimental Medicine, 174
N. Romani, S. Gruner, D. Brang, E. Kämpgen, A. Lenz, B. Trockenbacher, G. Konwalinka, P. Fritsch, R. Steinman, G. Schuler (1994)Proliferating dendritic cell progenitors in human blood
The Journal of Experimental Medicine, 180
A. Pel, E. Plaen, Bernard Leth, P. Coulie, T. Boon (1993)The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
The Journal of Experimental Medicine, 178
M. Papa, J. Mulé, S. Rosenberg (1986)Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Cancer research, 46 10
B. Gansbacher, R. Bannerji, Brian Daniels, K. Zier, K. Cronin, E. Gilboa (1990)Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity.
Cancer research, 50 24
D. Berd, H. Maguire, P. Mccue, M. Mastrangelo (1990)Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 8 11
Kayo Inaba, R. Steinman, Margit Pack, Hikeki Aya, M. Inaba, Tesuo Sudo, Stephen Wolpe, Gerold Schuler (1992)Identification of proliferating dendritic cell precursors in mouse blood
The Journal of Experimental Medicine, 175
R. Tepper, P. Pattengale, P. Leder (1989)Murine interleukin-4 displays potent anti-tumor activity in vivo
T. Itaya, S. Yamagiwa, F. Okada, T. Oikawa, N. Kuzumaki, N. Takeichi, M. Hosokawa, H. Kobayashi (1987)Xenogenization of a mouse lung carcinoma (3LL) by transfection with an allogeneic class I major histocompatibility complex gene (H-2Ld).
Cancer research, 47 12
B. Pulaski, A. McAdam, E. Hutter, S. Biggar, E. Lord, J. Frelinger (1993)Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dependent mechanism.
Cancer research, 53 9
G. Plautz, Zhi-yong Yang, Bei-yue Wu, Xiang Gao, Leaf Huang, G. Nabel (1993)Immunotherapy of malignancy by in vivo gene transfer into tumors.
Proceedings of the National Academy of Sciences of the United States of America, 90
A. Bakker, M. Schreurs, A. Boer, Y. Kawakami, S. Rosenberg, G. Adema, C. Figdor (1994)Melanocyte lineage-specific antigen gp100 is recognized by melanoma- derived tumor-infiltrating lymphocytes
The Journal of Experimental Medicine, 179
Rosenberg Sa (1988)Immunotherapy of patients with advanced cancer using interleukin-2 alone or in combination with lymphokine activated killer cells.
Important advances in oncology
M. Witmer-Pack, W. Olivier, J. Valinsky, G. Schuler, R. Steinman (1987)Granulocyte/macrophage colony-stimulating factor is essential for the viability and function of cultured murine epidermal Langerhans cells
The Journal of Experimental Medicine, 166
R. Lafrenière, S. Rosenberg (1985)Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
Journal of immunology, 135 6
Philip Livingston, A. Albino, Tae Chung, F. Real, A. Houghton, H. Oettgen, L. Old (1985)Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells
J. Pfeifer, M. Wick, R. Roberts, K. Findlay, S. Normark, C. Harding (1993)Phagocytic processing of bacterial antigens for class I MHC presentation to T cells
Robert Tepper, R. Coffman, P. Leder (1992)An eosinophil-dependent mechanism for the antitumor effect of interleukin-4.
Science, 257 5069
Advances in our understanding of the molecular events of antigen recogniÂ tion by T cells and T cell activation are opening up new approaches to cancer immunotherapy. The identification and cloning of cytokines provide one imporÂ tant set of tools for manipulating immunologic responses. For cancer therapy, cytokines such as interleukin-2 have been administered systemically. However, systemic administration of cytokines ignores the paracrine nature of their acÂ tion. Recently, an alternative approach has been explored that produces high concentrations of cytokines local to the tumor cells. This is achieved either by transduction of the tumor cells with the cytokine gene or by mixture of the tumor cells with cytokine containing biodegradable polymer microspheres. Under these circumstances, the locally released cytokine produces a strong local inflammatory T cell response results, capable of mediating regression of systemic tumor deÂ posits. This paracrine delivery of cytokines can therefore be considered as a new type of adjuvant in the design of vaccines for cancer as well as microbial infections. response specific to the particular cytokine. In some cases, a potent tumor-specific INTRODUCTION Two of the most actively investigated areas in cancer immunotherapy have been vaccines and cytokines. In the past, these two
Annual Review of Immunology – Annual Reviews
Published: Apr 1, 1995
Access the full text.
Sign up today, get DeepDyve free for 14 days.